Skip to main content

Collegium Pharmaceutical

Collegium Pharmaceutical Inc is an American commercial-stage specialty pharmaceutical enterprise focused on the development, manufacturing, and commercialization of innovative medicines for individuals suffering from chronic pain, addiction, and other central nervous system disorders, prominently featuring abuse-deterrent formulations such as Xtampza ER and Belbuca. The company utilizes proprietary drug delivery technologies to create pharmaceutical products designed to deter abuse while providing effective therapeutic relief. Its core business operations encompass specialty pharmaceutical manufacturing, clinical trial execution, commercial distribution, and FDA regulatory navigation. Revenue is derived primarily from direct prescription pharmaceutical product sales within the United States. Collegium Pharmaceutical holds a leading market position in abuse-deterrent pain management therapeutics. The company is headquartered in Needham, Massachusetts, United States, and its common stock trades on the Nasdaq Global Select Market.

4 of the funds FundTelligence covers report a position in Collegium Pharmaceutical.

Legal name
COLLEGIUM PHARMACEUTICAL INC
Sector
Health Care
Country
United States
Funds holding it
4

Funds holding Collegium Pharmaceutical

Loading...